First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.

Sebastiano Buti, Melissa Bersanelli, Francesco Massari, Ugo De Giorgi, Orazio Caffo, Gaetano Aurilio, Umberto Basso, Giacomo Carteni, Claudia Caserta, Luca Galli, Francesco Boccardo, Giuseppe Procopio, Gaetano Facchini, Giuseppe Fornarini, Alfredo Berruti, Elena Fea, Emanuele Naglieri, Fausto Petrelli, Roberto Iacovelli, Camillo PortaAlessandra Mosca

Research output: Contribution to journalArticlepeer-review


Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal phase III trials excluded patients with nccRCC, which constitute about 30% of metastatic RCC cases. To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup. The present study is a multicenter retrospective observational analysis aiming to assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting. Overall, 48 patients were included. At the median follow-up of 40.6 mo, the objective response rate was 27.1%, the disease control rate was 83.3%, and the median progression-free survival and overall survival were 12.3 (95% confidence interval [CI]: 3.6-20.9) and 27.7 (95%CI: 18.2-37.1) mo, respectively. Grade 3 adverse events occurred in 20% of patients, and no grade 4 or 5 toxicities were found. Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.
Original languageUndefined/Unknown
Pages (from-to)1037-1046
Number of pages10
JournalWorld Journal of Clinical Oncology
Publication statusPublished - Nov 1 2021


  • Kidney cancer
  • Non-clear cell
  • Pazopanib
  • Renal-cell carcinoma
  • Tyrosine kinase inhibitors
  • Variant histology

Cite this